RxDoctor Payments Data

Richard Maggio, MD

Urology · Staten Island, NYNPI 1205939998

Payments from drug & device makers

$5,468in general payments, 2019–2025

Across 177 payments — averaging $30.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$1K
  • Johnson & Johnson$546
  • Astellas Pharma US Inc$495
  • Procept Biorobotics Corporation$437
  • Tolmar, Inc.$367
  • AbbVie$285
  • plus $2K from 24 others

What the payments were for

  • Speaking & faculty fees$120%
  • Travel & lodging$52810%
  • Food & beverage$4,53083%
  • Education$3987%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,468 in reported general payments places this provider in the 65th percentile of 952 urology providers in New York.

See all urology providers in New York

Medicare billing

Part B allowed, 2024
$236,149
Medicare patients
454
Services billed
1,945

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide17$343,697
MyrbetriqMirabegron119$90,249
Solifenacin Succinate81$7,985
Tamsulosin Hcl366$6,804
Mirabegron ErMirabegron13$5,865
Silodosin23$3,232
Dutasteride51$2,618
Potassium Citrate ErPotassium Citrate13$1,830
Alfuzosin Hcl ErAlfuzosin Hcl63$1,661
Finasteride86$1,055
Oxybutynin Chloride ErOxybutynin Chloride56$742
Ciprofloxacin Hcl79$240
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav12$109
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim44$95

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$546$343,69717 claims
Astellas Pharma US IncMyrbetriq$495$90,249119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 952 urology providers in New York.

Other urology in Staten Island

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →